Gilead Sciences and LEO Pharma Alliance Targets Inflammatory Diseases
US-based major Gilead Sciences Inc. (NASDAQ: GILD) has formed a strategic alliance with Denmark-based dermatology...
Drug
Junshi Biosciences’ Mindewei Receives Full Approval in China
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that the conditional...
Ucello Biotech’s UC101 Receives FDA IND Clearance for Anti-CD19 Therapy
China-based Chengdu Ucello Biotechnology Co., Ltd., a developer of allogeneic universal chimeric antigen receptor (CAR)-T...
Hengrui’s Recaticimab Approved for Hypercholesterolemia Treatment
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that its Category 1 biologic...
Hengrui Pharmaceuticals Gets NMPA Approval for SHR-1819 Phase II Study
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received the...
Hengrui Pharmaceuticals Receives NMPA Approval for SHR-4375 Clinical Trial
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received clinical...
Bayer Files for Finerenone Approval in US and China for Heart Failure-Fineline Info & Tech
Bayer AG (ETR: BAYN) has announced market filings with the US Food and Drug Administration...
Pfizer’s Sasanlimab Shows Positive Results in Phase III CREST Study
US-based Pfizer Inc. (NYSE: PFE) has reported positive topline results from its pivotal Phase III...
NMPA Approves J&J’s FGFR Kinase Inhibitor Balversa for Urothelial Carcinoma
China’s National Medical Products Administration (NMPA) has approved Johnson & Johnson’s (J&J; NYSE: JNJ) FGFR...
Doma Biopharma Receives FDA Clearance for DM002 Phase I Study-Fineline Info & Tech
China-based Doma Biopharmaceutical (Suzhou) Co., Ltd has announced that it has received clearance from the...
GSK’s Shingrix Prefilled Syringe Accepted for FDA Review
UK-headquartered GlaxoSmithKline (GSK; NYSE: GSK) has announced that a market filing for a prefilled syringe...
Fosun Pharmaceutical’s FCN-437c Accepted for NMPA Review for Breast Cancer Treatment
Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) has announced that another market approval...
Hengrui’s SHR4640 Accepted for NMPA Review for Gout and Hyperuricemia Treatment
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that a market filing for...
Sinogen’s SalMet-Vec Receives FDA Orphan Drug Designation for Pancreatic Cancer
China’s oncology specialist Guangzhou Sinogen Pharmaceutical Co., Ltd. has announced receiving Orphan Drug Designation (ODD)...
Sanofi’s Sarclisa Meets Co-Primary Endpoints in Phase III IRAKLIA Study for Multiple Myeloma
French pharmaceutical giant Sanofi (NASDAQ: SNY, EPA: SAN) has announced that the Phase III IRAKLIA...
FDA Grants Priority Review to Johnson & Johnson’s Nipocalimab for Myasthenia Gravis
US-based Johnson & Johnson (J&J, NYSE: JNJ) has announced that the US FDA has granted...
Bayer’s Elinzanetant Meets All Primary Endpoints in Phase III OASIS 4 Study
Germany-based Bayer AG (ETR: BAYN) has announced that the Phase III OASIS 4 study for...
Inmagene Biopharmaceuticals Posts Positive Results for IMG-007 in Atopic Dermatitis
Inmagene Biopharmaceuticals, a Sino-US biotech that recently merged with US-based Ikena Oncology, Inc. (NASDAQ: IKNA),...
GSK Launches Cabotegravir Injection in China for HIV Pre-Exposure Prophylaxis
UK-based GlaxoSmithKline (GSK; NYSE: GSK) has announced the official commercial launch of its cabotegravir injection...
NHSA Revises 2024 NRDL Drug Information Based on Public Feedback
China’s National Healthcare Security Administration (NHSA) has announced revisions to the information about certain drugs...